Targets ANGPTL3 messenger RNA to reduce hepatic ANGPTL3 protein production. Source
Mixed hyperlipidemia: triglycerides 150–499 mg/dL plus elevated LDL or non-HDL cholesterol
Study contextCurrent approval status is not summarized in this therapy record. A trial phase or a brand name does not establish approval for this use.
Status & indicationsTriglycerides: 63 percentage-point reduction vs placebo · 24 weeks
ARCHES-2 · Phase 2 · Peer-reviewed trial · 200 mg on day 1 and week 12 · Placebo-adjusted mean percentage changes at week 24.
Evidence & limitationsA transient HbA 1c increase occurred in patients with diabetes receiving the highest dose.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
Triglycerides: 63 percentage-point reduction vs placebo · 24 weeks
200 mg on day 1 and week 12
Mixed hyperlipidemia: triglycerides 150–499 mg/dL plus elevated LDL or non-HDL cholesterol
Placebo-adjusted mean percentage changes at week 24.
A transient HbA 1c increase occurred in patients with diabetes receiving the highest dose.
Limitations: Phase 2 biomarker trial; cardiovascular-event benefit is unproven.
Status in this atlas: Current approval status is not summarized in this therapy record. A trial phase or a brand name does not establish approval for this use.
Targets ANGPTL3 messenger RNA to reduce hepatic ANGPTL3 protein production.
Mechanism sourceUses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
GalNAc-conjugated siRNA with two 21-nucleotide, chemically modified strands; the sense strand also carries inverted abasic subunits.
Shown: Chemically modified siRNA conjugate (ARO-ANG3).
The original phase 1 paper describes the molecular architecture and publishes its sequence in Supplementary Figure 3. No validated whole-drug 3D coordinates are included.
DOI 10.1038/s41591-023-02494-2; Methods and Supplementary Figure 3Zodasiran · compound history across indications
Selected sourced milestones, not a complete development history. Dates distinguish study starts, publications, announcements and approvals; the first listed date is not necessarily when development began.
The primary paper dates the first randomization in the ARO-ANG3 phase 1 basket study to January 4, 2019. The program enrolled healthy participants and cohorts with different lipid disorders.
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering — Nature Medicine (2023), study methodsNature Medicine reported first human proof of concept for the compound later named zodasiran: suppression of ANGPTL3 with reductions in triglycerides and atherogenic lipoproteins after single and repeated dosing.
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts — Nature Medicine (2023)The plotted randomized ARCHES-2 trial reported triglyceride and other lipid changes in adults with mixed hyperlipidemia. These biomarker findings do not establish a reduction in cardiovascular events.
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia — NEJM (2024)Selected sources checked Sep 14, 2026. This is not an exhaustive history.